New Drug vs Similar Drugs for Advanced Bladder Cancer
Treatments studied
Part of Brain & nervous system, Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares a new antibody-drug conjugate (sacituzumab tirumotecan) to other similar drugs for advanced bladder cancer that hasn't responded to prior treatment. It aims to see which is more effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder, ureter, or kidney-pelvis cancer that cannot be removed by surgery or has spread.
- You have already had at least one prior treatment (like chemo, immunotherapy, or targeted therapy).
- You have mild or no nerve damage in your hands or feet.
- You have not been treated with TROP2-targeted drugs or specific types of chemotherapy (irinotecan/topotecan).
- Your cancer is measurable on scans, and your overall health is good (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.